FDA Approves Merck’s KEYTRUDA (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM) Read more
BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy Read more
Cell Therapy Analytical and Quality Control Experts to Gather in Boston this December for the 6th Cell Therapy Analytical Development Summit Read more
Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ, to EMA and Health Canada Read more
MinervaX and Wacker Biotech Join Forces for Manufacturing of Prophylactic Vaccine Against Group B Streptococcus Read more
Nura Bio Closes Series A Financing with $68 Million in New Funds, Bringing Total Raised to $140+ Million Read more
Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’ Read more
Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma accepted for regulatory review in Japan Read more
FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer Read more